BidaskClub lowered shares of Intercept Pharmaceuticals (NASDAQ:ICPT) from a sell rating to a strong sell rating in a research note published on Tuesday morning.

Several other equities analysts have also weighed in on ICPT. Citigroup reaffirmed a neutral rating and set a $150.00 price objective on shares of Intercept Pharmaceuticals in a research report on Tuesday, September 19th. Jefferies Group reaffirmed a buy rating and set a $275.00 price objective on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 20th. Wells Fargo & Co lowered shares of Intercept Pharmaceuticals from an outperform rating to a market perform rating and cut their price objective for the company from $265.00 to $95.00 in a research report on Thursday, September 21st. ValuEngine lowered shares of Intercept Pharmaceuticals from a hold rating to a sell rating in a research report on Friday, September 22nd. Finally, Laidlaw cut their price objective on shares of Intercept Pharmaceuticals from $118.00 to $90.00 and set a hold rating on the stock in a research report on Friday, September 22nd. Four analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the company’s stock. Intercept Pharmaceuticals currently has an average rating of Hold and a consensus target price of $140.24.

Shares of Intercept Pharmaceuticals (ICPT) traded down $0.43 on Tuesday, reaching $52.55. 382,556 shares of the company traded hands, compared to its average volume of 951,190. The company has a market capitalization of $1,300.00, a price-to-earnings ratio of -3.55 and a beta of -2.05. The company has a debt-to-equity ratio of 3.15, a quick ratio of 5.95 and a current ratio of 5.95. Intercept Pharmaceuticals has a 52-week low of $52.11 and a 52-week high of $135.59.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share for the quarter, beating the consensus estimate of ($3.48) by $0.59. The firm had revenue of $41.33 million for the quarter, compared to analyst estimates of $36.95 million. Intercept Pharmaceuticals had a negative net margin of 344.74% and a negative return on equity of 176.51%. The company’s revenue for the quarter was up 697.9% on a year-over-year basis. During the same quarter last year, the firm earned ($3.59) earnings per share. research analysts expect that Intercept Pharmaceuticals will post -13.36 EPS for the current year.

Institutional investors have recently made changes to their positions in the company. WFG Advisors LP grew its stake in shares of Intercept Pharmaceuticals by 16.4% in the second quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 125 shares during the last quarter. QCM Cayman Ltd. acquired a new stake in shares of Intercept Pharmaceuticals in the second quarter worth $237,000. IFP Advisors Inc grew its stake in shares of Intercept Pharmaceuticals by 90.9% in the third quarter. IFP Advisors Inc now owns 2,482 shares of the biopharmaceutical company’s stock worth $144,000 after acquiring an additional 1,182 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Intercept Pharmaceuticals by 23.3% in the second quarter. PNC Financial Services Group Inc. now owns 2,490 shares of the biopharmaceutical company’s stock worth $302,000 after acquiring an additional 470 shares during the last quarter. Finally, Bayesian Capital Management LP acquired a new stake in shares of Intercept Pharmaceuticals in the second quarter worth $303,000. Institutional investors and hedge funds own 73.76% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was first posted by Daily Political and is the property of of Daily Political. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://www.dailypolitical.com/2018/01/17/intercept-pharmaceuticals-icpt-downgraded-by-bidaskclub-to-strong-sell.html.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.